#1COPYRIGHT © ABCELLERA Q2 2021 BUSINESS UPDATE AUG 12, 2021 AbCellera#2Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may,” “will,” “could,” “would," "should," “expect,” “intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3STRONG 19 GROWTH OF CORE BUSINESS LAR BIOLOGIC CLAS Q2 2021. BUSINESS UPDATE SUMMARY. AbCellera NEW programs under contract 6 NEW programs started 3 MOLECULES entered clinical testing Abtellera Nikon 138 cumulative programs under contract $792.6M in cash & cash equivalents $65M in accounts receivable (AR) + accrued AR#4Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4 2 ANTIBODIES FOR COVID-19 There is an increase in the number of COVID-19 cases globally, with over 100,000 daily cases reported in the US alone. bamlanivimab + etesevimab US shipments of bamlanivimab together with etesevimab halted in June because of the prevalence of resistant variants at the time (Gamma and Beta). Effective against Delta variant* bebtelovimab Currently in Phase 2 clinical trials alone and in combination with bamlanivimab and etesevimab. Effective against variants of concern, including the Delta variant* * Shown to be effective against the Delta variant in preclinical studies#5Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 DIVERSE PORTFOLIO THAT ALREADY COVERS MOST THERAPEUTIC AREAS PROGRAMS 138 UNDER CONTRACT therapeutic area KNOWN therapeutic area TBD oncology / neuro-degeneration / pain allergic inflammation / ophthalmology / infectious disease autoimmune diseases / women's health / genitourinary system / cardiovascular#6Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 UNLOCK NEW TARGETS Our partners look to us to unlock new targets across a range of target types. For targets that have been selected by our partners, a third include challenging, high-value targets: 28% DIFFICULT targets MUN multi-pass transmembrane targets high homology targets 72% STANDARD targets 83 & peptide-MHC targets#7Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 7 EMPOWER NEW MODALITIES FOR NEXT-GEN THERAPIES Our platform is an operating system designed to support many next-gen modalities, including: Y IgGs, IgMs, IgAs single chains (scFvs) CAR-T Cell therapies Y y bispecific antibodies radioisotope conjugates CNS-delivered antibodies#8Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 115 PUCS WITH DOWNSTREAM PARTICIPATION 46 PROGRAMS private & small cap biotech 40 PROGRAMS Our Programs Under Contract with downstream participation span the entire spectrum of drug development firms: mid & large cap biotech 24 PROGRAMS global pharma 5 PROGRAMS other industries#9Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT ABCELLERA DEVELOPMENT Antibody Discovery TECH STACK Preclinical Expansion into GMP/CMC manufacturing: PARTNER DEVELOPMENT Phase 1 AMATDA 1/01 Phase 2 Phase 3 & Approval AbCellera COMMERCIAL SALE#10Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 CREATE & CAPTURE VALUE WITH DEEPER POSITIONS Diverse deal structures provide the opportunity to deepen our position in successful molecules: Royalties & Milestones Option to Invest Equity / Equity-like#11Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11 CENTRALIZE INNOVATION TO MAKE DRUG DISCOVERY FASTER, MORE EFFICIENT & MORE COST EFFECTIVE. Genito Urinary System Infectious Disease Autoimmune Diseases Allergic Inflammation Single Chain Antibodies (scFvs) CNS-Delivered Antiibodies Public Health Oncology Venture Capital IgGs, IgMs, IgAs THERAPEUTIC AREAS Equity MODALITIES PARTNER TYPES Private & Small Cap Biotech DEAL TYPES Royalties & Milestones ABCELLERA Neuro- degeneration Bispecific Antibodies Large & Mid Cap Biotech Option to Invest Global Pharma Other Pain Ophthalmology CAR-T Cell Conjugates Radioisotope Conjugates Women's Health Cardiovascular#12o COPYRIGHT ABCELLERA Ⓒ Q2 2021 FINANCIALS UPDATE#13FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 13 Partnership business growth shows great strength in 1H 2021. # of Discovery Partners 35 30 25 20 15 10 5 27 33 1 HP 2015 2016 2017 2018 2019 2020 Q2 2021 Cumulative # of Programs Under Contract 140 120 100 80 60 40 20 WITHOUT downstream participation + WITH downstream participation 103 138 2015 2016 2017 2018 2019 2020 Q2 2021 Cumulative # of Program Starts 60 50 40 30 20 10 52 60 2015 2016 2017 2018 2019 2020 Q2 2021 Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.#14FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 14 Four molecules in the clinic, over a dozen in preclinical development. MOLECULE bamlanivimab (LY-CoV555) bebetelovimab (LY-CoV1404) NBL-012 NBL-015 STAGE Marketed, Emergency Use Authorization (EUA) Phase II Phase I IND approved PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BOTHERAPEUTICS THERAPEUTIC AREA ● COVID-19 COVID-19 dermatology • gastrointestinal disease immunology oncology PROGRAM TYPE AbCellera Discovery Partnership Trianni License#15FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 15 $27.6M revenue driven by COVID-19 program. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $11.2M $3.0M $8.2M Q2 2020 +2.5X 1 $27.6M $21.2M $1.0M $0.3M $5.2M Q2 2021 Note associated $3.6M royalty fee COVID-19 discovery program strong in Q2 2020#16FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 16 Operating expenses reflect continued strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT I 1 T 1 $9.1M Q2 2020 +$5.9M 1 I I $15.0M Q2 2021 SALES & MARKETING I I $0.5M Q2 2020 +$0.7M I $1.3M Q2 2021 GENERAL & ADMIN I I I I I $1.5M Q2 2020 +$9.7M $11.2M Q2 2021#17FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 17 Net loss of $2.3M: Equivalent to ($0.01) per share (basic & diluted). Earnings / Loss USD NET EARNINGS (LOSS) $6.7M Q2 2020 ($2.3M) Q2 2021 EARNINGS (LOSS) PER SHARE: BASIC & DILUTED $0.03 Q2 2020 ($0.01) Q2 2021#18FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 18 Operations results financed investments in H1 and further strengthened liquidity. Cash Flows USD $594.1M CASH & EQUIVALENTS 2020 Y/E $267.2M OPERATIONS ($61.5M) $20.5M $33.0M loans to JVs land INVESTMENT ($6.6M) FINANCING ($0.7M) FX Additionally, $65M AR + accrued AR balance at quarter end $792.6M CASH & EQUIVALENTS JUN 30#19Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 19 THANK YOU AbCellera Nikon ellera O a